This company develops a device for antimicrobial susceptibility testing, enabling rapid measurement and observation of cell growth and response in liquid samples. Their technology assists healthcare professionals by providing high-resolution measurement of mass in fluid and detecting positive growth, facilitating faster and more accurate diagnoses.

CellChorus provides the TIMING™ platform, a high‑throughput nanowell imaging system that uses visual AI to track and quantify migration, activation, cell‑cell interactions, cytotoxicity, and survival of thousands of individual immune cells in real time. The workflow generates single‑cell functional datasets that can be linked to multi‑omic profiling such as single‑cell RNA‑seq or flow cytometry, enabling researchers to identify and select the most effective cell candidates for immunotherapy development.

Chiara Biosciences develops next-generation, orally available small molecule degraders using an efficient discovery platform. The company focuses on creating novel medicines to address diseases that are currently undrugged or inadequately treated. This work aims to bring new therapeutic options to patients suffering from challenging conditions.

Glyphic Biotechnologies develops Protein Sequencing by Expansion (ProSE™), a novel technology for high-throughput proteome sequencing. This method achieves single-molecule sensitivity for accurate discrimination of all 20 amino acids and post-translational modifications (PTMs). The platform aims to provide unprecedented precision and scalability for advancing proteomics research and therapeutic development.

ResVita Bio develops a skin microbial platform utilizing genetically engineered bacteria to deliver therapeutic proteins directly to affected skin areas, providing continuous treatment for chronic skin diseases. The startup specifically targets conditions such as Netherton Syndrome and atopic dermatitis, addressing the need for sustained, localized therapies that minimize systemic side effects.

SAGA Diagnostics specializes in molecular residual disease (MRD) detection using a proprietary platform that combines next-generation sequencing and digital PCR to create patient-specific genetic fingerprints from tumor samples. This technology enables ultra-sensitive monitoring of residual cancer post-treatment, facilitating timely and informed therapeutic decisions through simple blood draws.